Patent intelligence · US
US 6204360
Retro-inverso thymosin alpha 1 hybrids
Retro-inverso thymosin alpha 1 hybrids
Patent details — US 6204360
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 20, 2001
- Expiration
- Mar 15, 2021
- Applicant
- USA Universe Bioengineering, Inc.
- Claims
- 2
- CPC classes
- A61K, A61K38/00
Quick answer
US 6204360 (Retro-inverso thymosin alpha 1 hybrids) is held by USA Universe Bioengineering, Inc.. Status: expired. Granted Mar 20, 2001. Expires Mar 15, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- USA Universe Bioengineering, Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K38/00
More from USA Universe Bioengineering, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 6204360?
US 6204360 (Retro-inverso thymosin alpha 1 hybrids) is held by USA Universe Bioengineering, Inc.. Status: expired. Granted Mar 20, 2001. Expires Mar 15, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6204360?
USA Universe Bioengineering, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 6204360 expire?
Our index shows an expiration date of Mar 15, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.